Novo Nordisk Investor Presentation - First Nine Months of 2016

B-cell function Investor presentation First nine months of 2016 Slide 36 Insulin is the ultimate care for people with diabetes Progression of type 2 diabetes and treatment intensification Distribution of patients and value across treatment classes Diet and exercise OAD: Oral anti-diabetic changing diabetes® Time OAD GLP-1 100% 80% 60% 40% Insulin 20% 0% Patients Insulin GLP-1 Value Note: Patient distribution across treatment classes is indicative and based on data for US, UK, Germany and France. Value figures based on IMS MAT August 2016 Source: IMS PharMetrix claims data, IMS disease analyser, IMS Midas OAD novo nordisk

View entire presentation